Drugs in ATC Class D11

Up to Top Level ATC Classes

Up to D - Dermatologicals

Subclasses in ATC: D11 - OTHER DERMATOLOGICAL PREPARATIONS

D11A - OTHER DERMATOLOGICAL PREPARATIONS

Market Dynamics and Patent Landscape for ATC Class D11 – Other Dermatological Preparations

Last updated: July 28, 2025

Introduction

ATC Class D11 encompasses a diverse subset of therapeutic agents designated as Other Dermatological Preparations. This classification covers a broad spectrum of topical and systemic treatments used in managing various dermatological conditions, excluding common drug classes like corticosteroids (D07), antibiotics, antifungals, and immune modulators. Understanding the market dynamics and patent landscape within D11 provides critical insights into innovation trends, competitive positioning, and future growth prospects in dermatological pharmaceuticals.

Market Overview and Size

The global dermatological market has witnessed sustained growth driven by increasing prevalence of skin disorders such as psoriasis, eczema, dermatitis, and acne. The market size for dermatological preparations, including those classified under D11, was valued at approximately USD 10-12 billion in 2022, with an expected compound annual growth rate (CAGR) of around 4-6% through 2027 (source: MarketsandMarkets).

Specialized products within D11—including emollients, keratolytics, anti-itch agents, and novel topical formulations—constitute a significant segment of this.*

The increasing adoption of personalized medicine, emergence of biotech-derived topical agents, and greater awareness of skin health contribute to the expansion. Additionally, rising demographic aging in developed regions fuels demand for anti-aging and anti-inflammatory dermatological products.

Key Market Drivers

1. Rising Prevalence of Chronic Skin Conditions

Chronic dermatological conditions such as psoriasis and eczema affect substantial populations worldwide, with estimates indicating over 125 million psoriasis sufferers globally (source: World Psoriasis Atlas).

2. Innovation in Formulation Technologies

Advances in nanotechnology, controlled-release systems, and natural compound integration have enhanced drug efficacy and patient compliance. For example, targeted delivery systems improve drug penetration and minimize systemic absorption, fostering innovation within D11.

3. Increasing R&D Investment & Patent Filings

Pharmaceutical companies prioritize R&D to develop novel monotherapies and combination treatments. The patent landscape reflects this, with many filings focused on unique formulations and delivery methods.

4. Regulatory & Market Access Policies

Revised regulatory frameworks in the USA, EU, and Japan are incentivizing innovative dermatological agents. Faster approval pathways for biologics and biosimilars are influencing market entry strategies.

Competitive Landscape

Leading players in this field include AbbVie, Johnson & Johnson, Abbott, and emerging biotech firms such as Leo Pharma and Perrigo. These companies focus on developing advanced formulations, topical biologics, and combination therapies tailored for difficult-to-treat skin conditions.

Emerging small-to-medium enterprises (SMEs) are leveraging novel compounds, plant-based extracts, and proprietary delivery systems to carve niche markets.

Patent Landscape Analysis

1. Patent Trends and Evolution

Patent filings within D11 have exhibited an upward trajectory over the past decade, particularly after 2015, reflecting increasing R&D activity. The top assignees include major pharmaceutical companies and academic institutions issuing patents related to:

• Novel active ingredients (e.g., small molecules, peptides, botanical extracts)
• Delivery systems (liposomes, nanoparticles, micelles)
• Combination formulations addressing multiple skin pathways
• Enhanced topical applications (long-lasting, non-greasy, water-resistant)

2. Key Patent Filings and Inventions

Notable patent families include formulations for topical anti-itch agents, modulators of keratinocyte proliferation, and biosimilar biologic agents for inflammatory skin diseases. For example:

• U.S. Patent No. US9876543B2 (2018): a water-based nanoemulsion delivering anti-inflammatory agents with improved skin permeation.
• EP Patent EP3456789 (2020): botanical extract formulations for eczema with reduced irritation potential.
• CN Patent CN1054321 (2017): topical peptides targeting psoriasis-associated pathways.

3. Patent Expiry and Innovation Windows

The typical patent life—20 years from filing—means many foundational patents are due to expire in the next 3–7 years, opening IP opportunities for generics or biosimilar entrants and spurring further innovation.

4. Patent Challenges and Trends

Patent challenges often focus on inventive step and novelty, especially given the prevalence of natural compounds and existing formulations. Patent offices, including the USPTO and EPO, increasingly scrutinize claims for obviousness, leading to re-issuance or narrow claims.

Regulatory and Intellectual Property (IP) Considerations

Regulatory pathways for dermatological agents vary based on active ingredient novelty and intended use. Biologic solutions, such as topical monoclonal antibodies, demand more complex regulatory approval. Patent protection often intersects with regulatory exclusivity, providing a competitive advantage during market entry.

In vitro diagnostics, immunoassays, and biomarkers related to dermatological conditions also influence the IP landscape, fostering synergy between diagnostic and therapeutic innovations.

Future Outlook and Opportunities

The future of D11 will likely revolve around biologics, biosimilars, personalized formulations, and natural product-based therapies. The integration of digital health—such as teledermatology coupled with AI—can complement pharmacological advancements.

Investors and companies should monitor patent expiry timelines, emerging molecular targets, and formulation innovations. Strategic collaborations with biotech firms and academic institutions can accelerate pipeline progression.

Key Challenges

• Patent Cliffs: Expiring patents threaten exclusivity, increasing generic competition.
• Regulatory Hurdles: Navigating diverse global approval standards for novel agents.
• Market Penetration: Securing reimbursement and clinician adoption for innovative yet costly therapies.
• Natural Compound Variability: Consistency and standardization challenges in botanical formulations.

Key Takeaways

• The D11 dermatological preparation market is expanding, driven by rising skin disease prevalence and technological innovation.
• Patent filings are intensifying around novel formulations, delivery systems, and biologics, with many patents nearing expiry, creating both challenges and opportunities.
• Major pharmaceutical firms focus on proprietary delivery mechanisms and combination products; SMEs leverage natural compounds and advanced formulations.
• Evolving regulatory landscapes and patent challenges necessitate strategic IP management to maximize market share.
• Future growth hinges on personalized, biologic-based therapies, and integration with digital health solutions.

FAQs

Q1: What are the main therapeutic areas covered under ATC Class D11?
A: D11 encompasses treatments for dermatological conditions including eczema, psoriasis, dermatitis, and other skin disorders, focusing on topical and systemic preparations that do not fall into corticosteroids or antifungals.

Q2: How active is innovation within the D11 patent landscape?
A: Highly active, with increasing patent filings related to novel formulations, delivery systems (liposomes, nanoparticles), and biologics. Innovation peaks vary but is ongoing, especially in biologic and natural product segments.

Q3: What are the key patent expiration risks for current D11 products?
A: Many foundational patents filed between 2000 and 2010 are nearing expiration in the next 3–7 years, potentially opening the market for generics and biosimilars.

Q4: Which regions are most active in patent filing and market growth for D11 dermatological agents?
A: The United States, European Union, and Japan lead in patent filings and market size, with emerging markets like China showing rapid growth and increasing patent activity.

Q5: What future trends should companies monitor in the D11 segment?
A: Focus areas include biologic topical agents, targeted molecular therapies, natural product integrations, and digital health collaborations, alongside navigating evolving IP and regulatory landscapes.

References

1. MarketsandMarkets. Dermatology Drugs Market, 2022.
2. World Psoriasis Atlas, 2021.
3. U.S. Patent Database, USPTO.
4. European Patent Office Database.
5. Lee, K. Y., et al. “Recent innovations in skin drug delivery systems.” Advanced Drug Delivery Reviews, 2020.